{"schema_version":"secwatch.filing_event.v1","accession":"0001764013-23-000090","form_type":"8-K","ticker":"IMVT","cik":"0001764013","company_name":"Immunovant, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.157889+00:00","generated_at":"2026-06-11T18:35:08.144194+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Immunovant reports Q1 net loss of $73.9M; IMVT-1402 Phase 1 data on track for September 2023","bullets":["Net loss $73.9M ($0.57/share) vs $40.4M ($0.35/share) in prior year; cash $330M funds ops into H2 2025.","R&D expenses rose to $50.6M (from $28.4M) driven by IMVT-1402 development and batoclimab milestones.","IMVT-1402 Phase 1 single-ascending dose data expected Sept 2023; multiple-ascending dose data Oct/Nov 2023.","Batoclimab Phase 3 MG data H2 2024; Phase 3 TED data H1 2025; CIDP Phase 2b initial data H1 2024; GD proof-of-concept Q4 2023.","Acquired IPR&D expenses $12.5M from batoclimab milestone achievement under HanAll agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001764013-23-000090","json":"https://secwatch.observer/filing/0001764013-23-000090.json","markdown":"https://secwatch.observer/filing/0001764013-23-000090.md","text":"https://secwatch.observer/filing/0001764013-23-000090.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1764013/000176401323000090/0001764013-23-000090-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1764013/000176401323000090/imvt-20230810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T18:35:08.144194+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9fcb6e6223b549516da241674d4d8f7fe3707f11","claim":"Immunovant, Inc. reported fiscal first quarter ended June 30, 2023 results: net income Net loss was $73.9 million ($0.57 per common share), EPS $0.57 per common share.","evidence_excerpt":"Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401323000090/0001764013-23-000090-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal first quarter ended June 30, 2023"},{"label":"Net income","value":"Net loss was $73.9 million ($0.57 per common share)"},{"label":"EPS","value":"$0.57 per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}